MedPath

Altabax

These highlights do not include all the information needed to use ALTABAX safely and effectively. See full prescribing information for ALTABAX. ALTABAX (retapamulin ointment), for topical use Initial U.S. Approval: 2007

Approved
Approval ID

7c91eee4-242b-4af2-a39b-7842a9d95143

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 5, 2023

Manufacturers
FDA

Almirall, LLC

DUNS: 605425912

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

retapamulin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code16110-518
Application NumberNDA022055
Product Classification
M
Marketing Category
C73594
G
Generic Name
retapamulin
Product Specifications
Route of AdministrationTOPICAL
Effective DateMay 10, 2018
FDA Product Classification

INGREDIENTS (2)

RETAPAMULINActive
Quantity: 10 mg in 1 g
Code: 4MG6O8991R
Classification: ACTIB
PETROLATUMInactive
Code: 4T6H12BN9U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Altabax - FDA Drug Approval Details